Introduction {#s1}
============

Colorectal cancer (CRC) and prostate cancer (PC) are among the most common malignancies worldwide, representing two of the top three most frequently diagnosed malignancies for men ([@B1]) Because of their high frequency, it is not uncommon for men to be diagnosed with both malignancies during their lifetime ([@B2]). Approximately one-sixth of men ≥50 years old with [\>]{.ul}10 years life expectancy undergoing PC screening prior to rectal cancer resection were noted to have a synchronous prostatic malignancy ([@B3]). Conversely, in men with newly diagnosed PC, screening colonoscopies identified synchronous CRC in \>3% of men in one study ([@B4]).

Synchronous presentation of both malignancies is less common than metachronous presentation; however, synchronous rates are increasing. Reasons for this increase are multifactorial, including increased screening for both malignancies, improved life expectancy, increased use of pelvic magnetic resonance imaging, and increased awareness ([@B5]--[@B7]). Along these lines, the American Cancer Society recently updated CRC screening guidelines for individuals at average risk to initiate regular screening at age 45 ([@B8]).

Management of synchronous PC and rectosigmoid cancer (RSC) is challenging given anatomic proximity of both malignancies and overlapping toxicity risks to surrounding tissues. There is a clinically unmet need in determining the preferred treatment for synchronous PC/RSC. A recent review article identified only 23 total published cases, with the largest case series comprised of only 10 patients ([@B6], [@B9]). Given the lack of prospective data to guide management, a retrospective, multi-institutional analysis was performed to analyze treatment patterns and outcomes for synchronous PC/RSC.

Methods {#s2}
=======

Patient Selection
-----------------

Men evaluated at Duke University Medical Center and the Durham Veterans Affairs Medical Center between 1988 and 2017 with diagnoses of both PC/RSC were identified using International Classification of Diseases (ICD)−9 and−10 codes. Electronic and paper medical records were reviewed to determine synchronous vs. metachronous presentation. Synchronous presentation was defined as objective documentation of clinical symptoms (e.g., hematochezia), laboratory data \[e.g., elevated prostate specific antigen (PSA) or fecal occult blood positive\], pathologic diagnosis, and/or primary treatment of one malignancy occurring within 12 months of the other. Exclusion criteria included: failure to meet the synchronous presentation definition; neuroendocrine histology; and primary cancer of the cecum, ascending, transverse or descending colon as well as anal canal.

Data Definitions
----------------

Patient age was defined as the age at the time of initial cancer diagnosis. The American Joint Committee on Cancer 7th edition TNM stage and stage group were recorded for both malignancies. For cases with sufficient information, prostate risk groups of low, favorable intermediate, unfavorable intermediate, high, and metastatic were manually assigned ([@B10], [@B11]). For PC patients initially opting for active surveillance prior to RSC diagnosis, the most recent PSA and staging information were documented at the time of active treatment. The highest combination of TNM-stage as well as stage group for RSC was recorded to account for downstaging effect following neoadjuvant chemoradiotherapy. Combined prostate and rectosigmoid surgeries were defined as synchronous surgery for both malignancies. Androgen deprivation therapy (ADT) was defined as surgical castration or the use of any medication lowering testosterone levels/blocking the testosterone receptor.

Statistical Methods
-------------------

The primary outcome was overall survival (OS), which was calculated from the date of latest cancer diagnosis to the date of death or last follow up. Secondary outcomes include PC biochemical failure \[Phoenix definition ([@B12])\], locoregional and distant recurrence of either malignancy, cause-specific survival, and crude incidence of grade ≥3 late toxicities. RSC locoregional recurrence was defined as pelvis or regional lymph nodes recurrence following primary treatment. Distant metastases (DM) were defined as imaging evidence of non-regional nodal, osseous, or visceral metastases. Late toxicities were scored using the Common Terminology Criteria for Adverse Events, version 5.0.

Descriptive summary statistics were performed on patient, tumor and treatment-related variables. OS was estimated via the Kaplan-Meier method, and cohort comparison performed via the log-rank test ([@B13]). Univariate and multivariable Cox regression analyses were also performed. Statistical analyses were conducted using STATA 15.1 (College Station, TX), with a *p*-value ≤ 0.05 considered statistically significant.

Results {#s3}
=======

Patient, Tumor, and Treatment Characteristics
---------------------------------------------

Among 31,883 men with PC identified, 330 (1%) also had RSC. Fifty-four (16%) of these were considered synchronous. By decade, there were 7, 16, and 31 men diagnosed with synchronous PC/RSC between 1988--1997, 1998--2007, and 2008--2017, respectively. The median age at diagnosis was 67 years. PC was more commonly the initial diagnosis (59%). Of these, 15 men underwent prostatectomy (*n* = 13) or radiotherapy (*n* = 2) prior to a diagnosis of synchronous RSC. [Table 1](#T1){ref-type="table"} summarizes patient, tumor, and treatment characteristics.

###### 

Patient, tumor, and treatment characteristics.

  **Variable**                                                              ***N* (%) or median (IQR)**                                                     
  ------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------
  Age (years)                                                               67 (62--72)                                                                     
  Latest year of cancer diagnosis                                           2009 (2004--2012)                                                               
  Sequence of malignant diagnoses                                           Prostate first                                                                  32 (59.3)
                                                                            Rectosigmoid first                                                              18 (33.3)
                                                                            Same date                                                                       4 (7.4)
  Pre-treatment prostate specific antigen (ng/mL)                           10.8 (6.7--29.3)                                                                
  T-stage of prostate cancer                                                T1b-T1c                                                                         16 (29.6)
                                                                            T2a-T2c                                                                         17 (31.5)
                                                                            T3a-T3b                                                                         9 (16.7)
                                                                            Unknown                                                                         12 (22.2)
  N-stage of prostate cancer                                                0                                                                               46 (85.2)
                                                                            1                                                                               2 (3.7)
                                                                            Unknown                                                                         6 (11.1)
  M-stage of prostate cancer                                                0                                                                               46 (85.2)
                                                                            1                                                                               2 (3.7)
                                                                            Unknown                                                                         6 (11.1)
  Prostate cancer risk group                                                Low                                                                             8 (14.8)
                                                                            Favorable intermediate                                                          8 (14.8)
                                                                            Unfavorable intermediate                                                        10 (18.5)
                                                                            High                                                                            19 (35.2)
                                                                            Metastatic                                                                      2 (3.7)
                                                                            Unknown                                                                         7 (13.0)
  T-stage of rectosigmoid cancer                                            T1                                                                              6 (11.1)
                                                                            T2                                                                              9 (16.7)
                                                                            T3                                                                              34 (63.0)
                                                                            T4                                                                              2 (3.7)
                                                                            Unknown                                                                         3 (5.6)
  N-stage of rectosigmoid cancer                                            0                                                                               27 (50.0)
                                                                            1a-1b                                                                           19 (35.2)
                                                                            2a-2b                                                                           5 (9.3)
                                                                            Unknown                                                                         3 (5.6)
  M-stage of rectosigmoid cancer                                            0                                                                               45 (83.3)
                                                                            1                                                                               9 (16.7)
  Stage group of rectosigmoid cancer                                        1                                                                               14 (25.9)
                                                                            2-3                                                                             31 (57.4)
                                                                            4                                                                               9 (16.7)
  Prostate surgical procedure                                               Biopsy only                                                                     33 (61.1)
                                                                            Prostatectomy                                                                   17 (31.5)
                                                                            Pelvic exenteration                                                             1 (1.9)
                                                                            TURP                                                                            1 (1.9)
                                                                            Cryoablation                                                                    1 (1.9)
                                                                            Unknown                                                                         1 (1.9)
  Rectosigmoid surgical procedure                                           Biopsy only                                                                     11 (20.4)
                                                                            Low anterior resection                                                          24 (44.4)
                                                                            Abdominoperineal resection                                                      10 (18.5)
                                                                            Transanal local excision                                                        7 (13.0)
                                                                            Pelvic exenteration                                                             1 (1.9)
                                                                            Unknown                                                                         1 (1.9)
  Combined surgery for both malignancies[^\*^](#TN1){ref-type="table-fn"}   2 (3.7)                                                                         
  Radiotherapy treatment                                                    None for prostate cancer                                                        24 (44.4)
                                                                            None for rectosigmoid                                                           28 (51.9)
                                                                            Prostate gland/bed only                                                         10 (18.5)
                                                                            Rectum and pelvic nodes without prostate gland/bed                              5 (9.3)
                                                                            Both malignancies treated in the same course                                    19 (35.2)
                                                                            Both malignancies treated in separate courses[^†^](#TN2){ref-type="table-fn"}   1 (1.9)
  Radiotherapy modality (n=35)                                              Brachytherapy alone                                                             2 (5.7)
                                                                            3D conformal                                                                    16 (45.7)
                                                                            IMRT                                                                            11 (31.4)
                                                                            Unknown                                                                         6 (17.1)
  Radiotherapy total dose (Gy)                                              Prostate                                                                        66 (60.7--72.1)
                                                                            Rectosigmoid                                                                    50.4 (50.4--54.0)
  Radiotherapy total fractions                                              Prostate                                                                        34 (29--38)
                                                                            Rectosigmoid                                                                    28 (28--30)
  5-FU based chemotherapy                                                   None                                                                            18 (33.3)
                                                                            Neoadjuvant                                                                     5 (9.3)
                                                                            Concurrent with radiotherapy                                                    23 (42.6)
                                                                            Adjuvant                                                                        13 (24.1)
                                                                            Palliative                                                                      3 (5.6)
                                                                            Unknown                                                                         2 (3.7)
  Androgen deprivation therapy                                              None                                                                            30 (55.6)
                                                                            Yes                                                                             23 (42.6)
                                                                            Unknown                                                                         1 (1.9)
  No treatment for prostate cancer                                          9 (16.7)                                                                        

IQR, Interquartile range; TURP, Transurethral resection of the prostate.

One patient underwent pelvic exenteration and another patient underwent combined abdominoperineal resection and open radical prostatectomy.

*Prostate brachytherapy followed 17 months later by 3D conformal external beam radiotherapy to the rectum and elective nodes with opposed lateral fields only to avoid overlap of previously irradiated tissues. The patient stopped treatment after 37.8 Gy due to intractable diarrhea requiring hospitalization*.

Approximately half (48%) of men had low or intermediate risk PC with a median pretreatment PSA of 10.8. Two men had nodal and DM from PC at diagnosis, and both had non-metastatic RSC. Nearly one-third (32%) of men underwent prostatectomy, 65% received radiotherapy, 43% received ADT, and 17% received no PC treatment.

The majority of RSC (93%) originated in the rectum. The stage group distributions were 26, 57, and 17% stage I, II--III, and IV, respectively. Low anterior resection (LAR) was more commonly performed compared to abdominoperineal resection (APR): 44 vs. 19%. Two men underwent combined surgery for both malignancies: one pelvic exenteration and one combined APR and open radical prostatectomy.

Nearly two-thirds of men received 5-FU-based chemotherapy (63%) and/or radiotherapy (65%). When administered, the most common radiotherapeutic strategy was to treat both malignancies in the same course (19/35 \[54%\]). The median prostate gland/fossa and rectosigmoid doses were 66 Gy and 50.4 Gy, respectively.

Survival Analysis
-----------------

After a median follow up of 43 months, 34 deaths occurred in the entire cohort. Median OS for the entire cohort was 58 months (95% confidence interval 39--106 months). Median OS for stage groups I, II--III, and IV RSC was not reached, 78 months and 13 months, respectively (*p* \< 0.001). Median OS for low/favorable intermediate risk, unfavorable intermediate risk, high risk, and metastatic PC was 73 months, not reached, 53 months, and 9 months, respectively (*p* \< 0.001).

[Table 2](#T2){ref-type="table"} summarizes the primary and secondary outcomes, including causes of death. More than half (53%) of deaths were attributed to progression of RSC. The next most likely cause of death was due to another non-prostate, non-rectosigmoid malignancy, specifically primary lung or hematologic malignancies (21%).

###### 

Clinical events of synchronous prostate and rectosigmoid cancers.

  **Variable**                              ***N* (%) or median (IQR)**                                  
  ----------------------------------------- ------------------------------------------------------------ -----------
  Follow up (months)                        43 (21--93)                                                  
  Prostate cancer outcomes (*n* = 54)       Biochemical failure                                          12 (22.2)
                                            Castrate resistance                                          3 (5.6)
                                            Distant metastasis                                           4 (7.4)
  Rectosigmoid cancer outcomes (*n* = 54)   Permanent colostomy                                          19 (35.1)
                                            Locoregional recurrence                                      4 (7.4)
                                            Distant metastasis                                           20 (37.0)
  Cause of death (*n* = 34)                 Grade 5 toxicity[^\*^](#TN3){ref-type="table-fn"}            3 (8.8)
                                            Prostate cancer progression                                  2 (5.9)
                                            Rectosigmoid cancer progression                              18 (52.9)
                                            Other malignancy[^†^](#TN4){ref-type="table-fn"}             7 (20.6)
                                            Unknown cause of death without recurrence of either cancer   4 (11.8)

IQR, Interquartile range.

One patient died from acute coronary syndrome after starting androgen deprivation therapy. Refer to [Table 3](#T3){ref-type="table"} for details of grade 5 gastrointestinal and genitourinary toxicities.

*3 deaths due to non-small cell lung cancer, 2 due to multiple myeloma, 1 due to acute myeloid leukemia, and 1 due to chronic lymphocytic leukemia and myelofibrosis*.

Three deaths were potentially attributable to treatment. One grade 5 gastrointestinal (GI) toxicity resulted from complications of hepatectomy for liver metastases. One grade 5 genitourinary (GU) toxicity occurred following combined APR and open radical prostatectomy who developed a vesicocutaneous fistula and later died from urosepsis. One patient died from acute coronary syndrome after starting ADT for metastatic PC.

[Table 3](#T3){ref-type="table"} summarizes multivariable analysis results evaluating the prognostic significance of known RSC stage and PC risk groups relative to OS. Stages II--III RSC were significantly associated with decreased OS, whereas none of the risk groups of non-metastatic PC were associated with OS. Metastatic disease from either malignancy was significantly associated with decreased OS. Similar findings were noted in multivariable Cox models evaluating the prognostic significance of RSC stage and PC risk groups relative to cause-specific survival ([Supplemental Table 1](#SM1){ref-type="supplementary-material"}). Neither age at diagnosis nor year of diagnosis were prognostic for OS on univariate analysis.

###### 

Univariate and multivariable Cox models relative to overall survival.

  **Variable**                           **Univariate (*****n*** **=** **54)**   **Multivariable[^\*^](#TN5){ref-type="table-fn"}** **(*****n*** **=** **47)**                       
  -------------------------------------- --------------------------------------- ------------------------------------------------------------------------------- ------------------- ---------
  **Prostate Cancer Risk Groups**                                                                                                                                                    
   Low/favorable intermediate risk       Reference                               --                                                                              Reference           --
   Unfavorable intermediate risk         0.70 (0.19--2.64)                       0.599                                                                           0.94 (0.24--3.67)   0.928
   High risk                             1.42 (0.62--3.26)                       0.410                                                                           0.75 (0.31--1.86)   0.486
   Metastatic                            10.99 (2.05--58.97)                     0.005                                                                           31.1 (4.64--208)    \<0.001
  **Rectosigmoid Cancer Stage Groups**                                                                                                                                               
   Stage I                               Reference                               --                                                                              Reference           --
   Stages II--III                        2.65 (0.89--7.88)                       0.080                                                                           4.26 (1.22--14.9)   0.023
   Stage IV                              7.96 (2.20--28.88)                      0.002                                                                           15.6 (3.19--76.8)   0.001
  Age at diagnosis                       1.03 (0.98--1.07)                       0.246                                                                           --                  --
  Year of diagnosis                      1.00 (0.94--1.06)                       0.953                                                                           --                  --

CI, confidence interval; HR, hazard ratio.

*The multivariable model excluded patients with unknown prostate cancer risk group*.

Locoregional and Biochemical Recurrence
---------------------------------------

Twelve men (22%) developed biochemical recurrence of PC and three (6%) met criteria for castrate resistance. Four men (7%) had locoregional recurrence of RSC.

Distant Metastasis
------------------

Twenty men developed DM from RSC compared to only four from PC. The most common sites of DM from RSC were liver then lung, with two developing peritoneal carcinomatosis and two brain metastases. All DM from PC were osseous, with or without nonregional lymph nodes.

Toxicity Analysis
-----------------

Overall, the crude incidence of late grade ≥3 GI and GU toxicity was 17 and 11%, respectively. The distribution of types and grades of toxicities stratified by surgical intervention are summarized in [Table 4](#T4){ref-type="table"}.

###### 

Late toxicities for synchronous prostate and rectosigmoid cancers.

  **Late toxicity**                     ***N*** **(%)**                                                                                                                     
  ------------------------------------- -------------------------------------------- ----------------------------------------- -------------------------------------------- ----------
  Received radiotherapy                 35 (64.8)                                    15 (75.0)                                 29 (69.0)                                    5 (55.6)
  GI grade 1--2                         7 (13.0)                                     4 (20.0)                                  7 (16.7)                                     1 (11.1)
  GI grade 3--4                         8 (14.8)                                     2 (10.0)                                  5 (11.9)                                     2 (22.2)
  GI grade 5                            1[^\*^](#TN6){ref-type="table-fn"} (1.9)     0 (0.0)                                   1[^\*^](#TN6){ref-type="table-fn"} (2.4)     0 (0.0)
  GU grade 1--2                         20 (37.0)                                    10 (50.0)                                 16 (38.1)                                    2 (22.2)
  GU grade 3--4                         5 (9.3)                                      2 (10.0)                                  4 (9.5)                                      0 (0.0)
  GU grade 5                            1[^†^](#TN7){ref-type="table-fn"} (1.9)      1[^†^](#TN7){ref-type="table-fn"} (5.0)   1[^†^](#TN7){ref-type="table-fn"} (2.4)      0 (0.0)
  Alpha blocker use                     7 (13.0)                                     1 (5.0)                                   6 (14.3)                                     1 (11.1)
  Erectile dysfunction medication use   6 (11.1)                                     5 (25.0)                                  6 (14.3)                                     0 (0.0)
  Penile pump implant                   2 (3.7)                                      2 (10.0)                                  2 (4.8)                                      0 (0.0)
  Permanent colostomy                   19 (35.2)                                    7 (35.0)                                  16 (38.1)                                    2 (22.2)
  Fistula                               4 (7.4)                                      2 (10.0)                                  2 (4.8)                                      1 (11.1)
  Pelvic/femur fracture                 1[^°^](#TN8){ref-type="table-fn"} (1.9)      0 (0.0)                                   1[^°^](#TN8){ref-type="table-fn"} (2.4)      0 (0.0)
  Secondary malignancy                  1[^\*\*^](#TN9){ref-type="table-fn"} (1.9)   0 (0.0)                                   1[^\*\*^](#TN9){ref-type="table-fn"} (2.4)   0 (0.0)

GI, gastrointestinal; GU, genitourinary.

Died from complications of hepatectomy for liver metastases.

Died from urosepsis as complication of vesicocutaneous fistula from combined abdominoperineal resection and open radical prostatectomy.

Right intertrochanteric femur fracture following a traumatic fall 12 months after completing radiotherapy.

*Transitional cell carcinoma of bladder diagnosed 9 years after 60 Gy of radiotherapy to the prostate and rectum*.

Approximately one-third of men underwent permanent colostomy placement: 19% due to APR and 17% due to toxicity or tumor recurrence. Four fistulas developed as a result of treatment and/or local tumor progression. As previously described, a vesicocutaneous fistula resulted from a combined APR/open prostatectomy. One iatrogenic rectourethral fistula resulted from a rectal biopsy to rule out recurrence 20 months following prostate gland intensity-modulated radiotherapy (76 Gy). Lastly, two men developed rectourethral fistulas following pelvic irradiation without colorectal surgery due to local progression of their RSC.

Eight men treated with LAR completed radiotherapy to both malignancies: six preoperatively and two postoperatively. Two treated postoperatively received a prostate boost totaling 60.4 Gy and 61 Gy, respectively, with no grade ≥3 toxicity. Two treated preoperatively with prostate external beam radiotherapy (EBRT) boost developed anastomotic leaks requiring ileostomy/colostomy: one who received 70.2 Gy and developed such within the perioperative period and another who received 76.4 Gy developed such 2.3 years following LAR. The EBRT technique in both cases was intensity-modulated radiotherapy. One patient with low risk PC received 160 Gy with low-dose rate interstitial I-125 brachytherapy seeds following LAR for T2N0M0 rectal adenocarcinoma with no evidence of disease recurrence or anastomotic leak 15 years later.

Of the 19 patients receiving concomitant radiotherapy for both malignancies in the same course, 17 received concurrent chemoradiotherapy and two sequential chemotherapy. Among these patients, two (11%) had late grade 3 GU toxicity and four (21%) had late grade 3 GI toxicity, including one patient who developed a fistula following treatment with 3D conformal radiotherapy to an unknown total dose. There were no grade 4 or 5 toxicities identified in this subgroup. Three patients ultimately required permanent ostomy: one due to salvage APR for local recurrence, one due to fistula formation, and one due to suspected anastomotic leak following ileostomy reversal. One patient developed right intertrochanteric femur fracture following a traumatic fall approximately one year following radiotherapy completion.

The entire study population demonstrated an increased risk of developing other malignancies, in addition to their known PC/RSC. Only one malignancy could be potentially attributed to radiotherapy in a patient diagnosed with transitional cell carcinoma of the bladder 9 years after receiving 60 Gy to the prostate and rectum. Other malignancies included a second/more proximal colon cancer, non-small cell lung cancer, multiple myeloma, leukemias, non-Hodgkin lymphoma, urothelial cancer of bladder or ureter, gastrointestinal stromal tumor, small bowel carcinoid tumor, larynx cancer, melanoma, and non-melanomatous skin cancers.

Discussion {#s4}
==========

To our knowledge, this analysis represents the largest study to date of men with synchronous PC/RSC. Coordinating optimal surgery and radiotherapy for anatomically proximate cancers of the prostate and rectosigmoid region in the same patient remains challenging as the least toxic treatment approach remains unknown for this increasingly common clinical conundrum.

Twenty-eight percent of men (*n* = 15) in this analysis received treatment for non-metastatic PC prior to RSC diagnosis. Synchronous diagnosis of lower gastrointestinal malignancy could have likely been made had those individuals undergone CRC screening before undergoing prostatectomy (*n* = 13) or radiotherapy (*n* = 2). Prior to prostate radiotherapy, radiation oncologists have been advised to obtain screening colonoscopy in these patients if not performed within the past 3 years, although similar recommendations have not been widespread prior to prostatectomy ([@B4], [@B14]). Based on results from a prior report, the number needed to screen to diagnose one synchronous asymptomatic CRC is about 31 ([@B4]). In the current study, approximately 1% of men were noted to have a metachronous or synchronous RSC, and this figure would be higher if the entire colon were considered. The majority of these 15 men had low or intermediate risk PC in the setting of 3 stage IV and 7 stage II-III rectosigmoid adenocarcinomas. It is possible that in some of these cases, the earlier synchronous diagnosis with colonoscopy could have resulted in a lower RSC stage at diagnosis and improved survival. It is also possible many of these patients received unnecessary prostate treatment with avoidable morbidity/complicating the ability to appropriately treat the synchronous RSC.

As might be anticipated, men with metastatic disease, whether due to PC or RSC, had significantly worse OS. Additionally, RSC was the predominant cause of mortality, accounting for the vast majority of DM and over half of total deaths. On multivariable analysis, RSC stage groups II-III were significantly associated with OS, whereas non-metastatic PC risk groups were not.

The median OS for stage I RSC (which was not reached and \>15 years in this study) is sufficiently long enough to warrant consideration of treatment of synchronous PC, even in low/intermediate risk groups. With a median OS of 6.5 years for patients with stage II-III RSC in this contemporary cohort, an individualized informed discussion regarding risks and benefits of treatment vs. observation for synchronous PC is recommended, as higher risk PC may warrant treatment while lower risk may not. Seventeen percent of men in this analysis received no PC-specific therapy, and it can be argued that this percentage should have been higher. Some proponents advocate for a course of ADT for selected patients with locally advanced RSC and PC in lieu of radiotherapy or surgery; however, the ADT risks of sexual dysfunction, bone demineralization, hot flashes, fatigue, sarcopenia, increased adiposity, gynecomastia, and cardiovascular complications need to be strongly considered.

If radiotherapy is utilized to treat RSC, a synchronous, localized PC can be treated simultaneously ([Figure 1](#F1){ref-type="fig"}) ([@B15]). One difficulty is that PC disease-related outcomes are improved with radiation dose escalation to levels higher than what is typically given for RSC, and the associated anterior rectal wall dose can be high enough to result in proctitis as well as anastomotic leak, fistula, or stricture following RSC surgery ([@B16], [@B17]). Options for prostate dose escalation include interstitial brachytherapy before, during, or after rectosigmoid surgery; EBRT boost before or after surgery; or no further irradiation following standard RSC treatment. If the irradiated rectum adjacent to the prostate receiving higher boost doses is resected, as is the case with APR, then late rectal toxicity is not relevant. However, when LAR is performed in an effort to avoid permanent colostomy, late toxicity related to the high dose prostate boost, particularly the rectal segment involving the anastomosis, can result in the previously described complications and definitive stoma. Exemplifying this, two men in our analysis treated with neoadjuvant EBRT for PC/RSC with a prostate radiation boost dose to \>70 Gy developed anastomotic leaks requiring surgical diversion, one of which occurred 2.3 years following LAR. Another series, which included seven men treated with 70--78 Gy preoperatively for synchronous PC followed by sphincter-preserving total mesorectal excision for rectal cancer, noted significantly increased rates of anastomotic leakage, reoperation, and definitive stoma requirement ([@B18]). In contrast, in another study with limited follow up, the only reported major complication among seven men receiving a prostate EBRT boost ≥70 Gy followed by LAR was a single case of anastomotic stricture ([@B9]). No patient in the present analysis received a prostate brachytherapy boost of any type, though a pre-LAR prostate boost with Cs-131 has been published as a proposed technique ([@B19]). Nevertheless, it is worth noting that one patient in the present analysis received definitive radiation to 160 Gy utilizing I-125 brachytherapy following LAR without complication, a dose much higher than what is conventionally administered as a boost.

![Intensity-modulated radiotherapy using simultaneous integrated boost technique to treat intact rectal and prostate cancers in 28 fractions. During treatment, the entire dose color wash volume is irradiated to differential doses on a daily basis. The primary rectal tumor, which is well visualized and surrounded by rectal contrast, receives a lower dose (green) compared to the entire prostate gland (orange-red). Note the relative sparing of the bladder anteriorly, the penile bulb inferiorly, and the small bowel superiorly.](fonc-10-00345-g0001){#F1}

A single combined operation for both malignancies, typically prostatectomy combined with either LAR or APR, can be performed ([@B20]--[@B25]). Minimally invasive surgical techniques, including laparoscopic APR ([@B24]) and robotic LAR ([@B23]), both combined with robotic-assisted prostatectomy, have been reported. In our multi-institutional analysis, two different combined open operations were performed: a pelvic exenteration as well as APR with prostatectomy. The former was successful, though potentially very morbid, whereas the second led to a vesicocutaneous fistula, repeated urinary tract infections, and eventual death from urosepsis.

Men with synchronous malignancies are at high risk of developing additional malignancies. About one-fifth (21%) of deaths in this analysis were attributable to a non-prostate/rectosigmoid, non-treatment-induced malignancy, the most common being non-small cell lung cancer and hematologic malignancies.

There are several limitations of our retrospective analysis, including incomplete medical records and selection bias. The number of patients screened for the other malignancy prior to the initial cancer diagnosis is unknown, and therefore the estimate of potential missed opportunities for earlier diagnosis is unknown. However, based on our data, about 590 men would need to be screened to identify a single man with synchronous PC and RSC. Additionally, performance status or comorbidity indices could not be included in the survival models to adjust for health status as these were not routinely documented or identifiable. Despite this being the largest study to date, the sample size remains small, particularly when limited to patients without DM at diagnosis. Furthermore, several patients had other, competing malignancies, though none of these had a documented malignancy preceding the synchronous diagnosis of PC and RSC, excluding non-melanomatous skin cancer.

Conclusions {#s5}
===========

Men ≥45 years old with newly diagnosed non-metastatic PC should undergo CRC screening prior to treatment to evaluate for synchronous colorectal malignancy if they have not had screening performed \<3 years previously. In patients with synchronous stage group II-IV RSC, the RSC is a significantly greater contributor to mortality relative to PC, and these patients may not require PC therapy. Prostate gland dose escalation with EBRT in the setting of sphincter-sparing colorectal surgery may increase the risk of anastomotic leakage and stenosis. Further investigation using interstitial brachytherapy boost techniques either pre-, intra- or post-operatively, is warranted.
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